The National Comprehensive Cancer Network considers multiple regimens to be acceptable for transplant-eligible patients with a new diagnosis of multiple myeloma. David Dingli, MD discussed the regimens that are currently available for patients.
Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.
The NCCN guidelines options available for patients with relapsed/refractory DLBCL include gemcitabine/oxaliplatin with or without rituximab, polatuzumab vedotin with or without bendamustine and rituximab, or the combination of bendamustine and rituximab alone.